The American Journal of Managed Care: How Revakinagene Taroretcel Can Benefit Patients With MacTel: Dr Charles Wykoff The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, ... Charles C.
Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ... Dr. Charles Wykoff is a board-certified retina surgeon with RCTX and currently serves as the Director of Research for our in-house research facility. Charles C.
dr charles wykoff, Wykoff, MD, PhD is Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. Learn more about Dr. Charles C. Wykoff, MD, PhD, in Bellaire, TX. Access to the profile, contact info, reviews, and more.
dr charles wykoff, Charles Wykoff, M.D., PhD. is the Director of Research at Retina Consultants of Texas, Chairman of Research, Retina Consultants of America, and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. Dr. Charles Wykoff grew up in Northern California and graduated Phi Beta Kappa from MIT (Massachusetts Institute of Technology). He received his Doctor of Philosophy in Molecular Biology from Oxford University in England while on a Marshal scholarship. Background education and training M.D., Harvard Medical School 2205 Ph.D., Oxford University (United Kingdom) 2001 B.S., Massachusetts Institute of Technology 1998 Contact full name Charles C.
Wykoff Dr. Charles C. Wykoff is an ophthalmologist in Bellaire, Texas and is affiliated with Houston Methodist Hospital and Memorial Hermann Surgery Center Kirby. He received his medical degree from...
